Teva buys BXCL501 rights from bankrupt BioXcel for up to $125m
Teva Pharmaceutical Industries has completed the acquisition of neuroscience assets from BioXcel Therapeutics, securing worldwide rights to BXCL501, an investigational dexmedetomidine sublingual film currently under FDA review. The deal, structured as a court-supervised Section 363 bankruptcy sale, cost Teva $57.5 million upfront with up to $67.5 million in contingent payments tied to regulatory approval timelines and commercial sales milestones.
BXCL501 is a supplemental NDA filed against BioXcel's already-approved product IGALMI, a dexmedetomidine sublingual film authorised for use in hospital settings to treat acute agitation in adults with schizophrenia or bipolar I or II disorder. If the FDA approves the supplemental application, BXCL501 would become the first approved at-home treatment for acute agitation in these populations, a meaningful step beyond the current clinical standard, which typically requires a healthcare setting for acute pharmacological intervention.
The deal
The acquisition was completed following Teva's selection as the winning bidder, court approval, and satisfaction of standard closing conditions. Teva did not acquire BioXcel Therapeutics as a corporate entity; the transaction covers the neuroscience asset portfolio only.
Evan Lippman, Teva's Executive Vice President for Business Development, described BXCL501 as a strong strategic fit, saying the company applies a "disciplined focus on differentiated, late-stage opportunities that address unmet patient needs and create long-term value." Eric Hughes, Teva's Chief Medical Officer, added that early intervention is central to the clinical rationale: "Agitation can escalate quickly, which is why the ability to intervene early matters."
Acute agitation affects an estimated 25 to 40 per cent of patients with schizophrenia or bipolar disorder, according to market research commissioned by Teva via Trinity Partners in March 2026. Episodes can escalate rapidly and frequently result in emergency department visits or hospitalisation, creating a clear burden for patients and caregivers, as well as a health-system cost argument for an effective at-home option.
Market context and regulatory path
The dexmedetomidine sublingual platform sits within a competitive neuroscience landscape that has attracted significant late-stage activity. Existing acute agitation treatments include intramuscular antipsychotics and benzodiazepines, both of which require clinical administration. An approved at-home formulation would occupy a largely uncontested niche, though commercial uptake will depend heavily on prescriber confidence, patient adherence, and payer willingness to reimburse outside the hospital setting.
For Teva, the deal advances its stated Pivot to Growth strategy, which prioritises adding innovative assets alongside its core generics and biosimilars business. The company already holds a neuroscience portfolio that includes treatments for migraine and movement disorders, and a late-stage CNS asset with potential first-in-class labelling for the at-home setting reinforces that positioning.
The FDA review timeline was not disclosed. Contingent payments include provisions for potential approval delays, suggesting Teva has modelled a range of regulatory scenarios. Investors will be watching for any update on the review clock, a potential advisory committee meeting, and, if approved, early prescribing data in the months following launch.
The bankruptcy context is also worth noting. BioXcel had struggled commercially with IGALMI since its 2022 approval, limiting the revenue base needed to fund BXCL501's development and NDA submission. Teva's acquisition through a Section 363 process, which allows assets to be sold free and clear of most liabilities, gives it a cleaner path to commercialisation than a traditional M&A structure would have afforded.